CFDE Data Portal | Search C16orf46-AS1

	Label	Description
	C16orf46-AS1 Gene (Entity type)	ENSG00000261838 - C16orf46 antisense RNA 1
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE155162 GSE155169 buparlisib 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 6 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE122979 GSE122980 LCL-161 MCF-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE138057 p53 HDAC8 inhibition 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 dasatinib 8 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS

C16orf46-AS1

ENSG00000261838 - C16orf46 antisense RNA 1

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE155162 GSE155169 buparlisib 1 v 3 human dn

A Gene Set from LINCS

GSE216043 cisplatin 11 v 4 human dn

A Gene Set from LINCS

GSE233679 nicotinamide 6 v 11 human dn

A Gene Set from LINCS

GSE122979 GSE122980 LCL-161 MCF-7 2 v 0 human up

A Gene Set from LINCS

GSE220806 progesterone fibroblast 0 v 3 human up

A Gene Set from LINCS

GSE216043 cisplatin 3 v 4 human up

A Gene Set from LINCS

GSE138057 p53 HDAC8 inhibition 0 v 1 human up

A Gene Set from LINCS

GSE135514 dasatinib 8 v 7 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.